Linda Mellbin

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes

Nikolaus Marx, Massimo Federici, Katharina Schütt et al. · European Heart Journal · 2023 · 1.4K citations · Full text

Medicine, Cardiology, Endocrinology +17

Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry

Kornelia Kotseva, Guy De Backer, Dirk De Bacquer et al. · European Journal of Preventive Cardiology · 2019 · 937 citations · Full text

Medicine, Cardiology, Interventional Cardiology +16

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

Guy De Backer, Piotr Jankowski, Kornelia Kotseva et al. · Atherosclerosis · 2019 · 369 citations · Full text

Medicine, Cardiology, Internal Medicine +14